Can ropinirole (Requip) be taken on an as‑needed (PRN) basis for restless‑legs syndrome (RLS)?

Ropinirole Should NOT Be Used PRN for Restless Legs Syndrome

The 2025 American Academy of Sleep Medicine (AASM) guidelines suggest AGAINST the standard use of ropinirole for RLS, and the drug is specifically designed for daily scheduled dosing, not PRN use. 1, 2

Why PRN Dosing Is Not Appropriate

Guideline Position on Ropinirole

The most recent 2025 AASM clinical practice guideline explicitly states that ropinirole should not be used as standard therapy for RLS (conditional recommendation, moderate certainty of evidence). The guideline notes that ropinirole may only be considered in patients who prioritize short-term symptom reduction over long-term adverse effects, particularly augmentation 1.

This recommendation reflects a fundamental shift away from dopamine agonists as first-line therapy due to the serious risk of augmentation—a paradoxical worsening of RLS symptoms that occurs with chronic dopaminergic therapy.

FDA-Approved Dosing Regimen

The FDA label for Requip (ropinirole) specifies a scheduled daily dosing regimen, not PRN use 2:

• Starting dose: 0.25 mg once daily, taken 1-3 hours before bedtime
• Titration over 7 weeks to optimal response
• Maximum dose: 4 mg daily for RLS
• The drug requires systematic dose escalation and cannot be stopped abruptly

Pharmacological Rationale Against PRN Use

Ropinirole is a dopamine agonist that requires:

• Steady-state plasma levels for efficacy
• Gradual titration to minimize side effects (nausea, dizziness, orthostatic hypotension)
• Gradual discontinuation to avoid withdrawal symptoms 2

PRN dosing would create erratic dopamine receptor stimulation, potentially:

• Increasing augmentation risk
• Causing unpredictable side effects
• Failing to provide consistent symptom control

What You Should Use Instead

First-Line Recommended Therapies (2025 AASM Guidelines)

Strong recommendations (Level A evidence):

• Gabapentin 1
• Pregabalin 1
• IV ferric carboxymaltose (if ferritin <75 μg/L and transferrin saturation <20%) 1

Conditional recommendations for consideration:

• Ferrous sulfate with vitamin C (check iron parameters first: ferritin, transferrin saturation) 1
• Extended-release oxycodone or other opioids (for refractory cases) 1
• Dipyridamole 1

Critical Pitfall: Augmentation

Augmentation is the most serious long-term complication of dopaminergic therapy, characterized by:

• Earlier onset of symptoms during the day
• Shorter latency to symptom onset when at rest
• Spread of symptoms to other body parts
• Increased symptom intensity

This risk makes scheduled dopaminergic therapy problematic, let alone PRN use 1, 3.

Clinical Algorithm for RLS Treatment

1. Check iron studies first: ferritin and transferrin saturation

   • If ferritin <75 μg/L: treat with oral iron (ferrous sulfate 325 mg with vitamin C 100-200 mg) 1, 4
   • If ferritin <75 μg/L with transferrin saturation <20%: consider IV iron 1

2. For moderate-to-severe symptoms requiring pharmacotherapy:

   • Start with gabapentin (300-1200 mg) or pregabalin (75-450 mg) taken 1-2 hours before symptom onset 1, 3
   • These alpha-2-delta ligands have lower augmentation risk than dopamine agonists

3. Reserve dopamine agonists (including ropinirole) only for:

   • Patients who fail alpha-2-delta ligands
   • Patients who explicitly prioritize short-term symptom relief over long-term augmentation risk
   • Always use scheduled daily dosing, never PRN 1, 2

4. For refractory cases:

   • Consider low-dose opioids (extended-release oxycodone) 1
   • Combination therapy under specialist guidance

Bottom Line

Ropinirole cannot and should not be used PRN for RLS. It requires scheduled daily dosing per FDA labeling, and current guidelines recommend against its standard use due to augmentation risk. Start with iron supplementation (if indicated) or alpha-2-delta ligands (gabapentin/pregabalin) as first-line therapy 1.